Microbiome Therapeutics: Global Markets

Feb 2023| BIO205B| BCC Publishing
Sample Report

Report Highlights

The global market for microbiome therapeutics is estimated to increase from $164.8 million in 2022 to reach $1.5 billion by 2027, at a compound annual growth rate (CAGR) of 54.8% from 2022 through 2027.

Report Includes

  • 32 data tables and 44 additional tables
  • An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics
  • Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
  • Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)
  • Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region
  • Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.
  • Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace
  • Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period
  • Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues
  • Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences

Report Scope

BCC Research’s new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others. The market is assessed in the following geographic regions: North America, Europe, and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.

Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.

Frequently Asked Questions (FAQs)

The microbiome therapeutics market is projected to grow from $141.7 million in 2021 to $1.5 billion in 2027, at a compound annual growth rate (CAGR) of 54.8% during the forecast period.
Key drivers of the microbiome therapeutics market are increasing validated and statistical microbiome data from human studies; expanding collaborations and strategic partnerships among academia and private players; continued investment by venture capitalists and pharma companies; and active support from the FDA.
The microbiome therapeutics market is segmented on the basis of strategy type, application, and region.
Additive microbiome therapeutics segment will dominate the market by the end of 2027.
Key companies in the market includes
  • 4D Pharma plc
  • AO Biome LLC
  • Vedanta Biosciences Inc.
  • Evelo Biosciences Inc.
  • Armata Pharmaceuticals Inc.
  • Enterome

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022-2027
Base year market size $141.7 million
Market size forecast $1.5 billion
Growth rate CAGR of 54.8% for the forecast period of 2022-2027
Units considered $ Millions
Segments covered treatment, application, and region
Regions covered North America, Europe, and emerging markets
Key Market Drivers
  • increasing validated and statistical microbiome data from human studies
  • expanding collaborations and strategic partnerships among academia and private players
  • continued investment by venture capitalists and pharma companies and active support from the FDA.
Companies studied
4D PHARMA
AO BIOME LLC
ASSEMBLY BIOSCIENCES INC.
ARMATA PHARMACEUTICALS
AZITRA INC.
BIOMICA
BIOMX
CHAIN BIOTECHNOLOGY LTD.
ELIGO BIOSCIENCE SAS
ENTEROME SA
EVELO BIOSCIENCES
FINCH THERAPEUTICS GROUP INC.
INTRALYTIX INC.
MAAT PHARMA
OSEL INC.
PYLUM BIOSCIENCES INC.
QUORUM INNOVATIONS LLC
REBIOTIX INC. (A FERRING COMPANY)
SECOND GENOME
SENDA BIOSCIENCES INC.
SERES THERAPEUTICS INC.
SFA THERAPEUTICS INC.
SYNLOGIC
THERIVA BIOLOGICS INC.
VEDANTA BIOSCIENCES INC.
YSOPIA BIOSCIENCE INC.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Microbiome Therapeutics: Global Markets175 $5,500 Free
Chapter- 1: Introduction8Free DownloadFree
Chapter- 2: Summary and Highlights3$250Free
Chapter- 3: Market and Technology Background23$740Free
Chapter- 4: Market Breakdown by Type of Therapeutic24$772Free
Chapter- 5: Market Breakdown by Application29$933Free
Chapter- 6: Industry Structure23$740Free
Chapter- 7: Patent Analysis9$289Free
Chapter- 8: Clinical Trials12$386Free
Chapter- 9: Analysis of Market Opportunities14$450Free
Chapter- 10: Company Profiles26$836Free
Chapter- 11: Appendix: Acronyms4$129Free
Published - Nov-2020| Analyst - Kamna Jhamb| Code - BIO205A

Report Highlights

The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.

Report Includes

  • 32 data tables and 47 additional tables
  • An in-depth overview of the global microbiome therapeutics market
  • Analyses of the global market trends, with data corresponding to market size for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
  • Latest information on market drivers and opportunities, challenges and restraints, technological developments, and regulatory updates, along with their impact on the stakeholders in this market
  • Evaluation of market potential for microbiome therapeutics market, their market share analysis on the basis of product types, applications, and regions
  • Highlights of this innovation driven microbiome therapeutics market covering current trends, disease areas of application, clinical trials and their stages, and new developments
  • Impact of COVID-19 pandemic on the global economy and delay in the clinical trial activity and financial effects on the overall growth of this market
  • Competitive landscape of this market featuring leading biopharmaceutical companies, their products pipeline and company share analysis
  • Key merger and acquisition deals, collaborations and partnerships, licensing and manufacturing agreements, and other notable investment strategies within this market
  • Patent review and deep-dive of the issued patents on the basis of categories such as type, year, disease type, company, country, and assignee
  • Profile description of the major market participants, including Azitra Inc., Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences Inc.
Microbiome Therapeutics: Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS